open access

Vol 77, No 1 (2019)
Original articles
Published online: 2018-11-07
Submitted: 2018-08-15
Accepted: 2018-11-07
Get Citation

Do we differ in terms of indications and demographics in cardiac resynchronisation recipients in Poland? Insights from the European CRT Survey II Registry

Damian Łasocha, Maciej Sterliński, Mateusz Tajstra, Krystian Josiak, Dariusz Zając, Sławomir Tłuczek, Adam Sokal, Łukasz J. Januszkiewicz, Bogdan Galar, Rafał Sznajder, Jarosław Kaźmierczak, Łukasz Szumowski, Camilla Normand, Cecilia Linde, Kenneth Dickstein
DOI: 10.5603/KP.a2018.0215
·
Pubmed: 30406939
·
Kardiol Pol 2019;77(1):40-46.

open access

Vol 77, No 1 (2019)
Original articles
Published online: 2018-11-07
Submitted: 2018-08-15
Accepted: 2018-11-07

Abstract

Background: Multiple randomised clinical trials have proven that cardiac resynchronisation therapy (CRT) reduces morbidity and mortality in appropriately selected patients with congestive heart failure and is recommended for such patients as per the European Society of Cardiology guidelines.

Aim: In this paper we compare the indications and demographics in cardiac resynchronisation recipients in Poland and other European countries.

Methods: In 2015 and 2016, physicians from 42 European countries participated in the second edition of the European Cardiac Resynchronisation Therapy Survey. For 14 months, 288 implanting centres gathered data regarding demography, indications, implanting methods, and guidance compatibility from 11,088 patients receiving CRT.

Results: The survey revealed that a vast group of patients were eligible for CRT implantation (although some of them with rela­tively weak guidance recommendations) and showed essential variety in clinical practice when national data were benchmarked.

Conclusions: The population of CRT recipients in Poland and other European countries did not differ in terms of demographic and clinical characteristics. In most cases, indications for CRT were in accordance with the guidelines; however some devices were implanted in patients beyond the guideline recommendations. For these procedures, the decision regarding CRT im­plantation relies mainly on the physicians’ experience.

Abstract

Background: Multiple randomised clinical trials have proven that cardiac resynchronisation therapy (CRT) reduces morbidity and mortality in appropriately selected patients with congestive heart failure and is recommended for such patients as per the European Society of Cardiology guidelines.

Aim: In this paper we compare the indications and demographics in cardiac resynchronisation recipients in Poland and other European countries.

Methods: In 2015 and 2016, physicians from 42 European countries participated in the second edition of the European Cardiac Resynchronisation Therapy Survey. For 14 months, 288 implanting centres gathered data regarding demography, indications, implanting methods, and guidance compatibility from 11,088 patients receiving CRT.

Results: The survey revealed that a vast group of patients were eligible for CRT implantation (although some of them with rela­tively weak guidance recommendations) and showed essential variety in clinical practice when national data were benchmarked.

Conclusions: The population of CRT recipients in Poland and other European countries did not differ in terms of demographic and clinical characteristics. In most cases, indications for CRT were in accordance with the guidelines; however some devices were implanted in patients beyond the guideline recommendations. For these procedures, the decision regarding CRT im­plantation relies mainly on the physicians’ experience.

Get Citation

Keywords

cardiac resynchronisation therapy, chronic heart failure, survey

About this article
Title

Do we differ in terms of indications and demographics in cardiac resynchronisation recipients in Poland? Insights from the European CRT Survey II Registry

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 77, No 1 (2019)

Pages

40-46

Published online

2018-11-07

DOI

10.5603/KP.a2018.0215

Pubmed

30406939

Bibliographic record

Kardiol Pol 2019;77(1):40-46.

Keywords

cardiac resynchronisation therapy
chronic heart failure
survey

Authors

Damian Łasocha
Maciej Sterliński
Mateusz Tajstra
Krystian Josiak
Dariusz Zając
Sławomir Tłuczek
Adam Sokal
Łukasz J. Januszkiewicz
Bogdan Galar
Rafał Sznajder
Jarosław Kaźmierczak
Łukasz Szumowski
Camilla Normand
Cecilia Linde
Kenneth Dickstein

References (24)
  1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007; 93(9): 1137–1146.
  2. Gąsior M, Pyka Ł, Gorol J, et al. COnteMporary Modalities In Treatment of Heart Failure: a report from the COMMIT-HF registry. Kardiol Pol. 2016; 74(6): 523–528.
  3. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013; 34(46): 3547–3556.
  4. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. 2007; 297(22): 2502–2514.
  5. Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol. 1994; 17(11 Pt 2): 1974–1979.
  6. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013; 34(29): 2281–2329.
  7. Sterliński M, Maciag A, Kowalski O, et al. Mortality in patients with heart failure treated with cardiac resynchronisation therapy. A long-term multi-centre follow-up study. Kardiol Pol. 2007; 65(11): 1287–1294.
  8. Abraham W, Fisher W, Smith A, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002; 346(24): 1845–1853.
  9. Dickstein K, Normand C, Auricchio A, et al. CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how? Eur J Heart Fail. 2018; 20(6): 1039–1051.
  10. Linde CM, Normand C, Bogale N, et al. Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II. Eur J Heart Fail. 2018; 20(10): 1457–1468.
  11. Dickstein K, Normand C, Anker SD, et al. European cardiac resynchronization therapy survey II: rationale and design. Europace. 2015; 17(1): 137–141.
  12. Tymińska A, Balsam P, Ozierański K, et al. Heart failure patients with a previous coronary revascularisation: results from the ESC-HF registry. Kardiol Pol. 2018; 76(1): 144–152.
  13. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005; 26(22): 2422–2434.
  14. Gitt AK, Bueno H, Danchin N, et al. The role of cardiac registries in evidence-based medicine. Eur Heart J. 2010; 31(5): 525–529.
  15. Wells G, Parkash R, Healey JS, et al. Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. CMAJ. 2011; 183(4): 421–429.
  16. WHO, Geneva: Switzerland; 2010. World Health Organization. Definition of an older or elderly person. http://www.who.int/healthinfo/survey/ageingdefnolder/en/index.html.
  17. Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med. 2014; 174(8): 1340–1348.
  18. Linde C, Ståhlberg M, Benson L, et al. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. Europace. 2015; 17(3): 424–431.
  19. Ozierański K, Kapłon-Cieślicka A, Peller M, et al. Clinical characteristics and predictors of one-year outcome of heart failure patients with atrial fibrillation compared to heart failure patients in sinus rhythm. Kardiol Pol. 2016; 74(3): 251–261.
  20. Cheng A, Landman SR, Stadler RW. Reasons for loss of cardiac resynchronization therapy pacing: insights from 32 844 patients. Circ Arrhythm Electrophysiol. 2012; 5(5): 884–888.
  21. Sipahi I, Carrigan TP, Rowland DY, et al. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med. 2011; 171(16): 1454–1462.
  22. Zareba W, Klein H, Cygankiewicz I, et al. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011; 123(10): 1061–1072.
  23. Thibault B, Harel F, Ducharme A, et al. LESSER-EARTH Investigators. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. Circulation. 2013; 127(8): 873–881.
  24. Steffel J, Varma N, Robertson M, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J. 2015; 36(30): 1983–1989.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl